Go to the list of all blogs
Allana's Avatar
published in Blogs
Aug 31, 2026
Why Is Agilon Health (AGL) Stock Down -8.36% Today?

Why Is Agilon Health (AGL) Stock Down -8.36% Today?

Key Takeaways

  • AGL shares fell 8.36% to $84.80, down $7.74 from the prior session's close of $92.54.
  • The decline followed a fresh bearish analyst note that kept an Underweight rating while setting a price target below the stock's previous closing level.
  • Valuation concerns are compounding after an extraordinary 2026 rally that lifted the shares from single digits.
  • Medicare Advantage margin pressures heading into 2027 remain a key overhang on the value-based care business.
  • Traders are watching upcoming earnings, membership-growth trends, and any shift in sell-side sentiment.

Opening Summary

agilon health, inc. (AGL), a Medicare-centric healthcare services company that partners with community-based physician groups through its value-based care platform, saw its shares fall sharply in Monday's session. The stock declined 8.36% to $84.80, a drop of $7.74 from Friday's close of $92.54. The move extended a period of elevated volatility for a name that has traded in an unusually wide range this year. Markets attributed the selling primarily to renewed bearishness on valuation, with JPMorgan maintaining an Underweight rating while adjusting its price target to $85 — a level that, despite being raised from a prior $31, still implied meaningful downside from where the stock had been trading.

Analyst Action and Valuation Reset

The immediate catalyst was a research update from JPMorgan, which kept its Underweight rating on AGL while adjusting its price target to $85. Although the revised target represented a sharp increase from the firm's previous $31 objective, the new level remained below Friday's closing price of $92.54, signaling that the analyst still sees the risk/reward skewed to the downside. For a stock that has delivered one of the most dramatic recoveries in the healthcare sector this year, a target below the prevailing price was enough to trigger an outsized market reaction.

Valuation Concerns After a Massive Rally

The sell-off reflects deeper unease about how much of agilon health's turnaround is already priced in. After trading near its 52-week low in the single digits, AGL surged hundreds of percent in 2026 as the company reported stronger revenue, profitability gains, and an upbeat guidance update. That dramatic appreciation left the shares trading at a premium to peers and made them highly sensitive to any shift in expectations. Sell-side analysts have repeatedly flagged that recent outperformance in medical margin and adjusted EBITDA was driven partly by favorable prior-year development, revised risk-adjustment estimates, and unusually benign cost trends — factors that may be difficult to sustain at the same magnitude.

Medicare Advantage Overhang

Beyond the single analyst note, investors continue to weigh structural risks in the Medicare Advantage market. As insurers seek to protect margins heading into 2027, value-based care providers such as AGL face contract-renegotiation risk and potential pressure on reimbursement economics. Management has prioritized profitability over membership volume, which supports near-term margins but could constrain longer-term revenue growth. That trade-off has left the market questioning whether the company's improved fundamentals can keep pace with its elevated valuation.

Market Context and Trading Activity

The move was broad-based across the healthcare services complex, though AGL stood out as a notable decliner given its high beta and recent volatility. The stock has logged dozens of moves greater than 5% over the past year, so today's decline, while significant, fits a pattern of sharp single-session swings. The decline pushed the shares decisively below the $92 area that had acted as recent support, leaving the stock vulnerable to further technical selling if sentiment does not stabilize. Trading volume reflected the continuation of a relatively subdued trend seen in recent sessions rather than a dramatic surge in selling pressure.

What Comes Next for AGL

Investors will be watching agilon health's next earnings report for confirmation that recent margin improvements are durable rather than one-time in nature. Membership growth, medical cost trends, and updates on payer contract negotiations will be closely scrutinized. Analyst sentiment remains divided, with a mix of Hold, Sell, and a minority of bullish ratings, underscoring genuine disagreement about the company's path to consistent profitability. Risks include any disappointment in risk-adjustment outcomes, renewed pressure on Medicare Advantage economics, and continued valuation compression if the broader rally in high-momentum healthcare names loses steam.

Trending AI Robots

For traders seeking a data-driven approach to volatile names like AGL, Tickeron's Trending AI Robots page offers a curated view of its strongest-performing automated strategies. Tickeron provides hundreds of AI trading bots covering thousands of tickers, but only the top performers under current market conditions are featured in this section. Bots vary by strategy, timeframe, performance metrics, and traded symbols, allowing users to explore approaches aligned with their own objectives. Explore the Trending AI Robots page to see which automated strategies are adapting best to today's market.

Disclaimer

The information on this webpage is provided for general informational and educational purposes only and is not intended as investment advice, a recommendation to purchase or sell any security, or an offer or solicitation related to investments. It does not consider your personal financial situation, goals, or risk profile, and all investing carries inherent risks, including the possibility of losing your entire investment. For more details, please review our full disclaimer.

Disclaimers and Limitations

Related Ticker: AGL

Contributor

Allana's AvatarAllana|Expert

Financial analyst and market blogger with expertise in equity research, fundamental analysis, and macroeconomic trends. I regularly publish coverage on individual stocks, ETFs, and sector developments — combining rigorous financial analysis with clear, engaging writing for a broad investment audience.


AGL in -0.56% downward trend, declining for three consecutive days on September 18, 2026

Moving lower for three straight days is viewed as a bearish sign. Keep an eye on this stock for future declines. Considering data from situations where AGL declined for three days, in 276 of 318 cases, the price declined further within the following month. The odds of a continued downward trend are 87%.

Price Prediction Chart

Technical Analysis (Indicators)

Bearish Trend Analysis

The Aroon Indicator for AGL entered a downward trend on September 10, 2026. This could indicate a strong downward move is ahead for the stock. Traders may want to consider selling the stock or buying put options.

Bullish Trend Analysis

The Stochastic Oscillator suggests the stock price trend may be in a reversal from a downward trend to an upward trend. 46 of 61 cases where AGL's Stochastic Oscillator exited the oversold zone resulted in an increase in price. Tickeron's analysis proposes that the odds of a continued upward trend are 75%.

The Momentum Indicator moved above the 0 level on September 15, 2026. You may want to consider a long position or call options on AGL as a result. In 60 of 78 past instances where the momentum indicator moved above 0, the stock continued to climb. The odds of a continued upward trend are 77%.

The Moving Average Convergence Divergence (MACD) for AGL just turned positive on September 08, 2026. Looking at past instances where AGL's MACD turned positive, the stock continued to rise in 39 of 43 cases over the following month. The odds of a continued upward trend are 90%.

Following a +5.75% 3-day Advance, the price is estimated to grow further. Considering data from situations where AGL advanced for three days, in 230 of 277 cases, the price rose further within the following month. The odds of a continued upward trend are 83%.

Fundamental Analysis (Ratings)

The Tickeron Price Growth Rating for this company is 34 (best 1 - 100 worst), indicating steady price growth. AGL’s price grows at a higher rate over the last 12 months as compared to S&P 500 index constituents.

The Tickeron Valuation Rating of 37 (best 1 - 100 worst) indicates that the company is fair valued in the industry. This rating compares market capitalization estimated by our proprietary formula with the current market capitalization. This rating is based on the following metrics, as compared to industry averages: P/B Ratio (6.579) is normal, around the industry mean (208.357). P/E Ratio (0.000) is within average values for comparable stocks, (175.235). Projected Growth (PEG Ratio) (0.000) is also within normal values, averaging (2.492). Dividend Yield (0.000) settles around the average of (0.005) among similar stocks. P/S Ratio (0.253) is also within normal values, averaging (2.688).

The Tickeron SMR rating for this company is 98 (best 1 - 100 worst), indicating weak sales and an unprofitable business model. SMR (Sales, Margin, Return on Equity) rating is based on comparative analysis of weighted Sales, Income Margin and Return on Equity values compared against S&P 500 index constituents. The weighted SMR value is a proprietary formula developed by Tickeron and represents an overall profitability measure for a stock.

The Tickeron PE Growth Rating for this company is 100 (best 1 - 100 worst), pointing to worse than average earnings growth. The PE Growth rating is based on a comparative analysis of stock PE ratio increase over the last 12 months compared against S&P 500 index constituents.

The Tickeron Profit vs. Risk Rating rating for this company is 100 (best 1 - 100 worst), indicating that the returns do not compensate for the risks. AGL’s unstable profits reported over time resulted in significant Drawdowns within these last five years. A stable profit reduces stock drawdown and volatility. The average Profit vs. Risk Rating rating for the industry is 87, placing this stock worse than average.

Notable companies

The most notable companies in this group are DaVita (NYSE:DVA), Community Health Systems (NYSE:CYH), WW International Inc (NASDAQ:WW).

Industry description

Hospital/Nursing Management companies own and operate health care facilities. Their operations include nursing homes, acute care facilities, retirement centers and outpatient surgery centers. HCA Healthcare Inc., Alcon Inc. and Universal Health Services, Inc. are some major companies in this industry. Technology has been at the forefront of development of advanced solutions, including quicker diagnoses of complex conditions. Investments in new diagnostics, healthcare IoT, and other healthcare technologies continue to gather momentum in this industry.

Market Cap

The average market capitalization across the Hospital/Nursing Management Industry is 4.85B. The market cap for tickers in the group ranges from 20.9K to 92.6B. HCA holds the highest valuation in this group at 92.6B. The lowest valued company is NMMCF at 20.9K.

High and low price notable news

The average weekly price growth across all stocks in the Hospital/Nursing Management Industry was -4%. For the same Industry, the average monthly price growth was -5%, and the average quarterly price growth was 37%. WW experienced the highest price growth at 8%, while BMGL experienced the biggest fall at -36%.

Volume

The average weekly volume growth across all stocks in the Hospital/Nursing Management Industry was 175%. For the same stocks of the Industry, the average monthly volume growth was 144% and the average quarterly volume growth was 26%

Fundamental Analysis Ratings

The average fundamental analysis ratings, where 1 is best and 100 is worst, are as follows

Valuation Rating: 55
P/E Growth Rating: 45
Price Growth Rating: 51
SMR Rating: 66
Profit Risk Rating: 87
Seasonality Score: -32 (-100 ... +100)
View a ticker or compare two or three
AGL
Daily Signal:
Gain/Loss:
Interact to see
Advertisement
A.I.Advisor
published price charts
A.I. Advisor
published General Information

General Information

Industry HospitalNursingManagement

Profile
Details
Industry
N/A
Address
440 Polaris Parkway
Phone
+1 562 256-3800
Employees
856
Web
https://www.agilonhealth.com
Interact to see
Advertisement
Shares of SailPoint, Inc. (SAIL) are tumbling approximately 12% in premarket trading on March 18, 2026, after the company released its fiscal fourth-quarter and full-year 2026 results before the market opened. While Q4 revenue came in slightly above consensus at $295 million (+23% year-over-year), investors were rattled by disappointing forward guidance for fiscal 2027.
Shares of KC surged approximately +17% in premarket trading on March 18, 2026, from a prior close of $13.12 to approximately $15.35. The primary catalyst is Kingsoft Cloud's release of its unaudited Q4 and full-year 2025 financial results before the U.S. market open, which appear to have significantly exceeded analyst expectations.
AngloGold Ashanti (AU) shares tumbled approximately 7% in premarket trading on March 18, 2026, extending a multi-week downtrend that has erased nearly 20% of the stock's value since late January highs. The primary catalyst driving the decline is persistent investor concern over AngloGold's lowered 2026 production guidance, with the company projecting gold output of 2.80–3.17 million ounces — a roughly 3% decline from its 2025 production of 3.1 million ounces.
AAOI shares surged approximately 10.90% in premarket trading on March 18, 2026, rising from a prior close of $86.33 to $95.74. The primary catalyst is strong positive sentiment generated at OFC 2026 — the Optical Fiber Communications Conference and Exhibition — where Applied Optoelectronics unveiled breakthrough laser and transceiver technology for next-generation AI data center infrastructure.
LITE shares surged approximately +12% in early Wednesday trading on March 18, 2026, with the stock changing hands near $727 compared to a prior session close of $649.56. The primary near-term catalyst is Lumentum's S&P 500 index inclusion, effective March 23, 2026, triggering front-running by institutional investors and mandatory buying by passive index funds.
Shares of New Era Energy & Digital, Inc. (NUAI) are trading down approximately 17% during today's session, with the prior close sitting at $5.56. The decline follows the company's March 17 business update conference call and webcast, held after market hours, during which management discussed the recently filed fiscal year 2025 annual report (Form 10-K).
Shares of Regencell Bioscience Holdings (RGC) are up approximately +16% intraday on March 18, 2026, trading at $26.56 against a prior close of $22.97. No single company-specific press release is driving today's move; the rally is primarily fueled by retail-driven momentum and short squeeze mechanics.
A jump in the Producer Price Index from 0.3% to around 0.7% month‑over‑month signals that wholesale inflation is re‑accelerating, delaying Fed rate‑cut hopes and reviving the “higher for longer” rates narrative.business. Likely winners in this environment include energy and commodity producers (XOM, CVX, TTE, COP), inflation‑resilient financials (JPM, BAC), and real‑asset plays like pipelines and infrastructure, which can pass through higher prices; ETFs like XLE, XOP, XLF, DBA, GLD offer diversified exposure.
BGSI fell more than 11% today, pulling back from recent levels around the high‑$150s as investors reassessed the risk‑reward following the Q4 2025 print and major U.S. expansion plans. Full‑year 2025 sales rose 2.4% to US$3.14 billion, but same‑store sales declined 0.2%, while reported net earnings fell 25% to US$18.4 million due to US$22.6 million in acquisition and transformation costs.
NG shares fell over 11% today, giving back a portion of steep gains that had taken the stock from near US$2.30 a year ago to recent highs around US$14.40 before the latest pullback. The decline follows a cluster of Donlin‑related announcements — including selection of Fluor as Bankable Feasibility Study (BFS) contractor and an infrastructure/energy letter of intent — which, while positive, highlighted the scale, cost and timeline of the project rather than near‑term cash generation.
SA dropped over 9% today, sliding from around US$30–31 toward the high‑US$27 range in morning trading, as recent optimism about a near‑term KSM partnership met renewed focus on execution and valuation risk. Recent analysis has highlighted that Seabridge’s 2026 “report card” allocates 55% of management’s performance weighting to KSM‑related goals, with securing a JV partner given the single largest weight at 30%, underscoring how concentrated the investment thesis has become.
CABO shares fell over 11% today, sliding from the low‑US$110s toward the US$100 area, extending a brutal 12‑month decline of roughly 55% and bringing the stock closer to the bottom of its 52‑week range near US$70. Q4 2025 results showed a 6.1% year‑over‑year revenue drop to US$363.7 million, with residential data revenue down 4.2% and business data off 1.3%; full‑year revenue fell to about US$1.5 billion from US$1.6 billion in 2024.
In a market rattled by geopolitical tension, tariff uncertainty, and Fed rate volatility, one category of stocks continues to electrify traders: penny stocks, microcaps, and small-caps. These sub-$5 shares can surge 50%, 100%, or even 150% in a single session on a news catalyst — but without the right tools, most retail traders get caught on the wrong side. Enter Tickeron's two powerhouse AI robots: the Small-Cap Stocks - AI Trend Trader 60min (FA) and the Penny Stock - MicroCap Signal Bot 60min (FA).
Elite Returns in a Volatile Sector — Both robots delivered annualized returns above 94%, outperforming the vast majority of active semiconductor funds. High Consistency — Win rates of 68–71% mean these robots win more often than they lose — a rare edge in a sector famous for violent swings.
Exceptional Returns: +79.13% annualized return on a starting balance of $8,040.74, demonstrating consistent alpha generation in the comms-tech sector. High Win Rate: 59.43% of trades close in profit, with a Profit Factor of 2.65 — meaning every $1 risked historically returns $2.65.
Tight Risk Management — The 3% TP / 2% SL corridor keeps risk-reward structured and disciplined, cutting losses quickly while locking in gains before reversals. Right Tickers, Right Time — XOM, CVX, and COP are all up roughly 30% year-to-date in 2026, making them among the most high-momentum, liquid energy plays in the market right now.
AngloGold Ashanti (AU) shares are tumbling approximately 11% in premarket trading on March 19, 2026, extending a steep multi-week correction that has now erased more than 35% of the stock's value from its March 2 peak of $129.14. The primary sustained catalyst driving the decline is AngloGold's lowered 2026 production guidance, projecting gold output of 2.80–3.17 million ounces — a mid-point decline versus the company's 2025 output of approximately 3.1 million ounces, and below analyst expectations.
CSIQ shares tumbled approximately 18% in premarket trading on March 19, 2026, following the release of deeply disappointing Q4 2025 earnings before the open. The company reported a net loss of $1.66 per diluted share, far worse than the Wall Street consensus estimate of -$0.98, representing a 69% earnings miss.
YRD shares are tumbling approximately 17% in premarket trading on March 19, 2026, from a prior close of $3.68 to approximately $3.05, following the company's release of Q4 and full-year 2025 financial results before the U.S. market open. Primary catalyst: A dramatic swing to net loss in Q4 2025. Yiren Digital reported a Q4 net loss of RMB 882.2 million (~USD 126.1 million), compared to net income of RMB 331.4 million in Q4 2024 — a more than $250 million deterioration year-over-year.
Shares of MU are down approximately 6.66% in premarket trading on March 19, 2026, sliding from a prior close of $461.73 to around $431.00. Despite a historic earnings beat — fiscal Q2 2026 revenue of $23.86 billion versus the $19.19 billion consensus, and adjusted EPS of $12.20 against an $8.79 estimate — the stock is experiencing a classic "sell the news" reaction.